Dianabol vs Pramipexole
Well Studied vs FDA Approved
synergistic Mechanism-based · 55% Pramipexole supports hormonal recovery from suppression caused by Dianabol. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life.
Molecular Data
Dianabol Pramipexole
Weight 300.44 Da 211.33 Da
Half-life ~4-6 hours ~8 hours
Type 17-alpha-alkylated anabolic steroid (C20H28O2) Non-ergoline dopamine D3 receptor agonist
Key Benefits
Dianabol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Significant strength gains within the first 1-2 weeks
03 Enhanced nitrogen retention and protein synthesis
04 Improved glycogenolysis and muscular endurance
05 Pronounced muscle fullness and pumps from increased intracellular water and glycogen
06 Effective oral kickstart while waiting for injectable compounds to saturate
07 One of the fastest-acting anabolic compounds available
Pramipexole
01 Suppresses prolactin elevation caused by 19-nor anabolic steroids
02 Non-ergoline structure eliminates the risk of cardiac valve fibrosis associated with ergot-derived agents like cabergoline
03 Generally cheaper and more widely available than cabergoline
04 FDA-approved with a well-characterized safety and pharmacokinetic profile
05 Can restore sexual function impaired by prolactin elevation on nandrolone or trenbolone cycles
06 Viable alternative when cabergoline cannot be sourced
Side Effects
Dianabol
Significant water retention and bloating (estrogen-mediated)
Elevated blood pressure from fluid retention and increased red blood cell mass
Liver stress with elevated ALT/AST enzymes (dose and duration dependent)
Back pumps (painful lower back cramping during exercise)
Increased appetite
Oily skin and acne
Suppression of endogenous testosterone production (HPTA suppression)
Mild mood changes (increased aggression, irritability, or euphoria)
Pramipexole
Nausea (very common during initiation; typically resolves with continued use)
Drowsiness and somnolence (often taken at bedtime to manage this)
Dizziness or lightheadedness
Headache
Insomnia (in some users, despite drowsiness being more typical)
Orthostatic hypotension (feeling faint when standing up quickly)
Contraindications
Pre-existing liver disease or impaired hepatic function
Active or history of hormone-sensitive cancers (prostate, breast)
Uncontrolled hypertension or significant cardiovascular disease
Elevated hematocrit (above 54%) at baseline
Concurrent use of other hepatotoxic oral steroids (do not stack C17-aa orals)
Pregnancy or potential exposure to pregnant women
Heavy alcohol use (compounded hepatotoxicity risk)
Cholestatic liver conditions or history of drug-induced liver injury
Known hypersensitivity to pramipexole or any component of the formulation
Concurrent use of other dopamine agonists (cabergoline, bromocriptine)
History of impulse control disorders or pathological gambling
Severe renal impairment (pramipexole is primarily renally excreted; dose adjustment required in moderate impairment)
Concurrent use of dopamine antagonists (antipsychotics, metoclopramide) which oppose pramipexole's mechanism
Research Evidence
Dianabol Pramipexole
Status Well Studied FDA Approved
References 5 studies 5 studies
Latest 2017 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.